Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-20

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether 18F-Al-NOTA-MATBBN is safety and effective for cancer diagnosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics

NCT02441972

Tumors Carcinoma, Bronchogenic Breast Carcinoma +3 more

UNKNOWN PHASE1

18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor

NCT06126705

Tumor, Solid

RECRUITING EARLY_PHASE1

A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

NCT03511768

Neuroendocrine Neoplasm

UNKNOWN PHASE1/PHASE2

18F-FSPG PET/CT Imaging in Patients With Cancers

NCT03144622

Pulmonary Cancer Breast Neoplasms Abdominal Cancer

UNKNOWN

18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma

NCT04813705

Nasopharyngeal Carcinoma

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Observe radiation dose to healthy volunteers and patients; the correlation between integrin level and tumor/metastases uptake.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Neoplasms Prostatic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Open Label

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

18F-Al-NOTA-MATBBN PET/CT

Imaging with 18F-Al-NOTA-MATBBN PET/CT

Group Type EXPERIMENTAL

18F-Al-NOTA-MATBBN PET/CT

Intervention Type DRUG

18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.

PET/CT

Intervention Type DEVICE

Imaging with 18F-Al-NOTA-MATBBN PET/CT.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

18F-Al-NOTA-MATBBN PET/CT

18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.

Intervention Type DRUG

PET/CT

Imaging with 18F-Al-NOTA-MATBBN PET/CT.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Volunteers or patients with age more than 18 yeas;
2. The patients have been diagnosed with cancer or suspected with cancer;
3. It must fulfill the ethical requirements and subjects have signed an informed consent.

Exclusion Criteria

1. Pregnancy or nursing mothers;
2. Having drugs or alcohol dependence;
3. Hypersensitive to the active or inactive ingredients of the study drug;
4. Having attended other drug clinical trials within three months;
5. Cardiac functional insufficiency;
6. Hepatic and renal function insufficiency;
7. Hypertensive patients with serious complications;
8. Endangering the safety of life.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes